Trial Profile

A small randomized, placebo-controlled study of Emcitate in United States

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tiratricol (Primary)
Indications Allan-Herndon-Dudley syndrome
Focus Therapeutic Use
Sponsors Egetis Therapeutics

Most Recent Events

23 May 2023 According to an Egetis Therapeutics media release, the company intends to submit a new drug application (NDA) in the US for Emcitate in the fourth quarter of 2023 under the Fast-Track Designation granted by FDA.
27 Jan 2023 According to an Egetis Therapeutics media release, the company intends to initiate this study after discussion with the FDA.
01 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com